Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer’s disease.
The interim study included 24 patients who were divided into three groups: a sham stimulation control group, a low-frequency treatment group and a high-frequency treatment group.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Each subject received treatment over eight weeks, and the efficacy of the treatment was evaluated both during the trial and over the course of the subsequent eight-week period.
Treatment using deep TMS was well-tolerated by all subjects, with no side-effects.
Efficacy was evaluated using the Alzheimer’s Disease Assessment Scale – Cognitive test and a quality-of-life scale.
The results suggest that high-frequency treatment leads to improvement on Alzheimer’s disease assessment scales, whereas low-frequency and sham treatment do not.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
